Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | PPID | Q08752 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL268058 | 1.00 | MEN1 (0.37) | MEN1KMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL268072 | 1.00 | MEN1 (0.37) | MEN1KMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL31164267 | 1.00 | MEN1 (0.37) | MEN1KMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL2223205 | 0.83 | GABRP (0.37) | MEN1KMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL261165 | 0.82 | LMNA (0.37) | MEN1KMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL2637205 | 0.82 | LMNA (0.37) | MEN1KMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL8274565 | 0.82 | ALDH1A1 (0.36) | MEN1KMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL261164 | 0.82 | LMNA (0.37) | MEN1KMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL28520075 | 0.81 | KMT2A (0.33) | MEN1KMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL28342663 | 0.80 | RNPEP (0.38) | MEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134023-B2 | Preparation of pregabalin and related compounds | PFIZER INC (US) | 2012-03-13 | — | — | US | disclosed |
| US-20120015412-A1 | Preparation of Pregabalin and Related Compounds | PFIZER INC | 2012-01-19 | — | — | US | disclosed |
| US-8044227-B2 | Preparation of pregabalin and related compounds | PFIZER INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110065168-A1 | Preparation of Pregabalin and Related Compounds | PFIZER INC | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065168-A1 | Preparation of Pregabalin and Related Compounds | GABRE, GABRG1, GABRA6 | MEN1 4300/4885KMT2A 2049/4885GAA 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.